Next Article in Journal / Special Issue
DNA Virus Vectors for Vaccine Production in Plants: Spotlight on Geminiviruses
Previous Article in Journal
Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer’s Disease Like Tau Aggregation
Previous Article in Special Issue
Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8+ T Cell Epitopes
Open AccessReview

Developments in Viral Vector-Based Vaccines

Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, Japan
Author to whom correspondence should be addressed.
Vaccines 2014, 2(3), 624-641;
Received: 22 April 2014 / Revised: 18 June 2014 / Accepted: 30 June 2014 / Published: 29 July 2014
(This article belongs to the Special Issue Vaccine Vector)
PDF [497 KB, uploaded 29 July 2014]


Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last several decades, many types of viruses have been developed as vaccine vectors. Each has unique features and parental virus-related risks. In addition, genetically altered vectors have been developed to improve efficacy and safety, reduce administration dose, and enable large-scale manufacturing. To date, both successful and unsuccessful results have been reported in clinical trials. These trials provide important information on factors such as toxicity, administration dose tolerated, and optimized vaccination strategy. This review highlights major viral vectors that are the best candidates for clinical use. View Full-Text
Keywords: viral vector; vaccine; CTL; MVA; adenovirus viral vector; vaccine; CTL; MVA; adenovirus
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Ura, T.; Okuda, K.; Shimada, M. Developments in Viral Vector-Based Vaccines. Vaccines 2014, 2, 624-641.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top